Skip to main content
OpenTrials
Completed

NCT Number: NCT02774343

PPARγ Agonist Treatment for Cocaine Dependence

The purpose of this research study is to determine whether a medication called pioglitazone (trade name Actos) can reduce behavioral problems associated with cocaine use, improve brain structural changes associated with cocaine use and reduce cocaine craving and drug use in cocaine dependent patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cocaine Use Disorder Alcohol Use Disorder Alcohol-Related Disorders Alcoholism Chemically-Induced Disorders Mental Disorders Substance-Related Disorders

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

The University of Texas Health Science Center at Houston

Houston, Texas, 77030, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • DSM-IV criteria for cocaine dependence
  • At least one cocaine positive urine during screening
  • Female subjects: a negative pregnancy test
  • Be in acceptable health on the basis of interview, medical history and physical exam
  • Be able to understand the consent form and provide written informed consent
  • Be able to provide the names of at least 2 persons who can generally locate their whereabouts.

Exclusion criteria

  • Current Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV diagnosis of any psychoactive substance dependence other than cocaine marijuana, alcohol, or nicotine
  • Any serious medical or psychiatric illness and/or clinically significant abnormal laboratory value, which in the judgment of the Principal Investigator or his/her designee would make study participation unsafe, or would make treatment compliance difficult or put the study staff at undue risk
  • Significant current suicidal or homicidal ideation
  • Medical conditions contraindicating pioglitazone pharmacotherapy (e.g., congestive heart failure as determined by Framingham criteria, clinically significant edema, clinically significant liver disease, hypoglycemia, diabetes, history of bladder cancer)
  • Taking medications known to have significant drug interactions with the study medication (CYP2C8 inhibitors or inducers, antihyperglycemic medications)
  • Currently being treated for substance misuse with medication
  • Conditions of probation or parole requiring reports of drug use to officers of the court
  • Impending incarceration
  • Pregnant or planning to become pregnant during the course of the trial or nursing for female patients
  • Inability to read, write, or speak English (many of the research instruments in this study only exist in English)
  • Having plans to leave the immediate geographical area within 3 months
  • Unwillingness to sign a written informed consent form
  • Unwillingness to use a barrier method of birth control during the study for female patients
  • History of pacemaker or metal implants or welding or metal work without protective eyewear (for risk of MRI scans).

Treatment and study plan

pioglitazone

Drug

Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.

Other names: Actos

Placebo

Drug

Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.

Other names: corn starch

Therapy

Behavioral

Cognitive-behavioral therapy 1 hour per week

Contingency Management

Behavioral

Prize-based contingency management for attendance

Primary outcomes

  1. Craving as Assessed by the Brief Substance Craving Scale (BSCS)

    Time frame: Baseline, week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 11, week 12

    The brief substance craving scale (BSCS) is a 16-item, self-report instrument assesses craving for cocaine and other substances of abuse over a 24 hour period. The domains of intensity, frequency, and duration are recorded on a five-point Likert scale. The range of scores for each domain is 0 to 4, and the total score is the sum of all three domains. The total score range is 0 to 12, and higher scores indicate higher craving (worse outcome.)

  2. Craving as Assessed by the Obsessive Compulsive Drug Use Scale (OCDUS)

    Time frame: Weeks 1-12

    The obsessive compulsive drug use scale (OCDUS) measures the level of craving for cocaine during the past week. The mean score over all time points is reported in this outcome measure (i.e., a summary score is reported). The scale was administered once weekly. It consists of 12 items. The score range is 0 to 60, and higher scores indicates greater craving.

  3. Cue Reactivity as Assessed by a Visual Analogue Scale (VAS) of Cocaine Craving

    Time frame: Baseline, week 2, week 4, week 6, week 8, week 10, week 12

    Every two weeks, visual analog scale ratings of craving (VAS craving) consisting of 100 mm line, anchored by 0 "not at all" and 100 "extremely," were used to assess cocaine craving right now, craving on average in the past week, and the worst craving in the past week. Data were analyzed as a total score, which is the sum of the scores for the three questions.

  4. Brain White Matter (WM) Integrity as Assessed by Diffusion Tensor Imaging (DTI) Fractional Anisotropy (FA) Value (Region - Posterior Thalamic Radiation)

    Time frame: Baseline and Week 12

    DTI scans were acquired on a Philips Integra 3T magnet. Fractional anisotropy (FA) is a summary measure of the integrity of white matter neurons that provides a dimensionless index of the expected movement of water molecules inside and across the neuron. Higher values of FA indicate better neuronal integrity (that is, less movement of water across the neuron). There is no range of values, as this is a dimensionless index.

  5. Brain White Matter (WM) Integrity as Assessed by Diffusion Tensor Imaging (DTI) Fractional Anisotropy (FA) Value (Region - Anterior Thalamic Radiation)

    Time frame: Baseline and Week 12

    DTI scans were acquired on a Philips Integra 3T magnet. Fractional anisotropy (FA) is a summary measure of the integrity of white matter neurons that provides a dimensionless index of the expected movement of water molecules inside and across the neuron. Higher values of FA indicate better neuronal integrity (that is, less movement of water across the neuron). There is no range of values, as this is a dimensionless index.

  6. Brain White Matter (WM) Integrity as Assessed by Diffusion Tensor Imaging (DTI) Fractional Anisotropy (FA) Value (Region - Splenium of Corpus Callosum)

    Time frame: Baseline and Week 12

    DTI scans were acquired on a Philips Integra 3T magnet. Fractional anisotropy (FA) is a summary measure of the integrity of white matter neurons that provides a dimensionless index of the expected movement of water molecules inside and across the neuron. Higher values of FA indicate better neuronal integrity (that is, less movement of water across the neuron). There is no range of values, as this is a dimensionless index.

  7. Brain White Matter (WM) Integrity as Assessed by Diffusion Tensor Imaging (DTI) Fractional Anisotropy (FA) Value (Region - Genu of Corpus Callosum)

    Time frame: Baseline and Week 12

    DTI scans were acquired on a Philips Integra 3T magnet. Fractional anisotropy (FA) is a summary measure of the integrity of white matter neurons that provides a dimensionless index of the expected movement of water molecules inside and across the neuron. Higher values of FA indicate better neuronal integrity (that is, less movement of water across the neuron). There is no range of values, as this is a dimensionless index.

  8. Brain White Matter (WM) Integrity as Assessed by Diffusion Tensor Imaging (DTI) Fractional Anisotropy (FA) Value (Region - External Capsule)

    Time frame: Baseline and Week 12

    DTI scans were acquired on a Philips Integra 3T magnet. Fractional anisotropy (FA) is a summary measure of the integrity of white matter neurons that provides a dimensionless index of the expected movement of water molecules inside and across the neuron. Higher values of FA indicate better neuronal integrity (that is, less movement of water across the neuron). There is no range of values, as this is a dimensionless index.

  9. Brain White Matter (WM) Integrity as Assessed by Diffusion Tensor Imaging (DTI) Fractional Anisotropy (FA) Value (Region - Cingulum)

    Time frame: Baseline and Week 12

    DTI scans were acquired on a Philips Integra 3T magnet. Fractional anisotropy (FA) is a summary measure of the integrity of white matter neurons that provides a dimensionless index of the expected movement of water molecules inside and across the neuron. Higher values of FA indicate better neuronal integrity (that is, less movement of water across the neuron). There is no range of values, as this is a dimensionless index.

Secondary outcomes

  1. Feasibility - Subject Retention as Assessed by Number of Participants Who Completed All 12 Weeks of the Study

    Time frame: week 12

  2. Feasibility - Medication Compliance as Assessed by Percentage of Urine Samples That Were Riboflavin-Positive

    Time frame: weeks 1 - 12

    Riboflavin was added to pill capsules as a marker of medication compliance. The percentage over all time points is reported in this outcome measure. Urine samples were collected once weekly.

  3. Feasibility - Medication Compliance as Assessed by Percentage of Self-reports That Indicate Capsules Were Taken

    Time frame: weeks 1 - 12

    A modified Timeline Followback (TLFB) procedure was used for self-reports. The percentage over all time points is reported in this outcome measure. Self-reports were collected once weekly.

  4. Feasibility - Tolerability as Assessed by Number of Participants Reporting Side Effects

    Time frame: week 12

  5. Feasibility - Tolerability as Assessed by Number of Participants With Serious Adverse Events

    Time frame: week 12

  6. Cocaine Use as Assessed by Percentage of Urine Samples That Were Cocaine-positive

    Time frame: Weeks 1-12

    The mean percentage over all time points is reported in this outcome measure. Urine samples were collected once weekly.

  7. Cocaine Use as Assessed by Percentage of Self-reports That Indicate Cocaine Use

    Time frame: Weeks 1-12

    A modified Timeline Followback (TLFB) procedure was used to assess cocaine use. The mean percentage over all time points is reported in this outcome measure. Self-reports were collected once weekly.

Sponsors and collaborators

Lead sponsor

The University of Texas Health Science Center, Houston

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
May 17, 2016
Registry last updated
Apr 26, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.